Literature DB >> 31175169

Inflammatory markers in cerebrospinal fluid: independent prognostic biomarkers in amyotrophic lateral sclerosis?

Benjamin Gille1,2, Maxim De Schaepdryver1,3, Lieselot Dedeene1,3, Janne Goossens1, Kristl G Claeys4,5, Ludo Van Den Bosch6,7, Jos Tournoy2,8, Philip Van Damme4,7, Koen Poesen9,3.   

Abstract

OBJECTIVE: Inflammation is a key pathological hallmark in amyotrophic lateral sclerosis (ALS), which seems to be linked to the disease progression. It is not clear what the added diagnostic and prognostic value are of inflammatory markers in the cerebrospinal fluid (CSF) of patients with ALS.
METHODS: Chitotriosidase-1 (CHIT1), chitinase-3-like protein 1 (YKL-40) and monocyte chemoattractant protein-1 (MCP-1) were measured in CSF and serum of patients with ALS (n=105), disease controls (n=102) and patients with a disease mimicking ALS (n=16). The discriminatory performance was evaluated by means of a receiver operating characteristic curve analysis. CSF and serum levels were correlated with several clinical parameters. A multivariate Cox regression analysis, including eight other established prognostic markers, was used to evaluate survival in ALS.
RESULTS: In CSF, CHIT1, YKL-40 and MCP-1 showed a weak discriminatory performance between ALS and ALS mimics (area under the curve: 0.79, p<0.0001; 0.72, p=0.001; 0.75, p=0.001, respectively). CHIT1 and YKL-40 correlated with the disease progression rate (ρ=0.28, p=0.009; ρ=0.34, p=0.002, respectively). CHIT1 levels were elevated in patients with a higher number of regions displaying motor neuron degeneration (one vs three regions: 4248 vs 13 518 pg/mL, p = 0.0075). In CSF, YKL-40 and MCP-1 were independently associated with survival (HR: 29.7, p=0.0003; 6.14, p=0.001, respectively).
CONCLUSIONS: Our findings show that inflammation in patients with ALS reflects the disease progression as an independent predictor of survival. Our data encourage the use of inflammatory markers in patient stratification and as surrogate markers of therapy response in clinical trials. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  amyotrophic lateral sclerosis; biomarker; inflammation; survival

Mesh:

Substances:

Year:  2019        PMID: 31175169     DOI: 10.1136/jnnp-2018-319586

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  22 in total

1.  Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis.

Authors:  Samir Abu-Rumeileh; Veria Vacchiano; Corrado Zenesini; Barbara Polischi; Silvia de Pasqua; Enrico Fileccia; Angela Mammana; Vitantonio Di Stasi; Sabina Capellari; Fabrizio Salvi; Rocco Liguori; Piero Parchi
Journal:  J Neurol       Date:  2020-02-25       Impact factor: 4.849

2.  Serum NfL and CHI3L1 for ALS and parkinsonian disorders in the process of diagnosis.

Authors:  Shotaro Haji; Wataru Sako; Nagahisa Murakami; Yusuke Osaki; Yuishin Izumi
Journal:  J Neural Transm (Vienna)       Date:  2022-02-18       Impact factor: 3.850

3.  Urinary neopterin: A novel biomarker of disease progression in amyotrophic lateral sclerosis.

Authors:  Stephanie R Shepheard; Vassilios Karnaros; Beben Benyamin; David W Schultz; Megan Dubowsky; Joanne Wuu; Tim Chataway; Andrea Malaspina; Michael Benatar; Mary-Louise Rogers
Journal:  Eur J Neurol       Date:  2022-01-11       Impact factor: 6.288

Review 4.  Non-neuronal cells in amyotrophic lateral sclerosis - from pathogenesis to biomarkers.

Authors:  Björn F Vahsen; Elizabeth Gray; Alexander G Thompson; Olaf Ansorge; Daniel C Anthony; Sally A Cowley; Kevin Talbot; Martin R Turner
Journal:  Nat Rev Neurol       Date:  2021-04-29       Impact factor: 42.937

5.  Altered perivascular fibroblast activity precedes ALS disease onset.

Authors:  Anna Månberg; Nathan Skene; Folkert Sanders; Marta Trusohamn; Julia Remnestål; Anna Szczepińska; Inci Sevval Aksoylu; Peter Lönnerberg; Lwaki Ebarasi; Stefan Wouters; Manuela Lehmann; Jennie Olofsson; Inti von Gohren Antequera; Aylin Domaniku; Maxim De Schaepdryver; Joke De Vocht; Koen Poesen; Mathias Uhlén; Jasper Anink; Caroline Mijnsbergen; Hermieneke Vergunst-Bosch; Annemarie Hübers; Ulf Kläppe; Elena Rodriguez-Vieitez; Jonathan D Gilthorpe; Eva Hedlund; Robert A Harris; Eleonora Aronica; Philip Van Damme; Albert Ludolph; Jan Veldink; Caroline Ingre; Peter Nilsson; Sebastian A Lewandowski
Journal:  Nat Med       Date:  2021-04-15       Impact factor: 87.241

6.  CSF chitinases before and after symptom onset in amyotrophic lateral sclerosis.

Authors:  Elizabeth Gray; Alexander G Thompson; Joanne Wuu; Joe Pelt; Kevin Talbot; Michael Benatar; Martin R Turner
Journal:  Ann Clin Transl Neurol       Date:  2020-07-14       Impact factor: 4.511

7.  Transmission of ALS pathogenesis by the cerebrospinal fluid.

Authors:  Pooja Shree Mishra; Hejer Boutej; Geneviève Soucy; Christine Bareil; Sunny Kumar; Vincent Picher-Martel; Nicolas Dupré; Jasna Kriz; Jean-Pierre Julien
Journal:  Acta Neuropathol Commun       Date:  2020-05-07       Impact factor: 7.801

8.  Cognitive and Neuronal Link With Inflammation: A Longitudinal Study in People With and Without HIV Infection.

Authors:  Albert M Anderson; Jeong Hoon Jang; Kirk A Easley; Dietmar Fuchs; Magnus Gisslen; Henrik Zetterberg; Kaj Blennow; Ronald J Ellis; Donald Franklin; Robert K Heaton; Igor Grant; Scott L Letendre
Journal:  J Acquir Immune Defic Syndr       Date:  2020-12-15       Impact factor: 3.731

Review 9.  Interplay between immunity and amyotrophic lateral sclerosis: Clinical impact.

Authors:  Fabiola De Marchi; Ivana Munitic; Amedeo Amedei; James D Berry; Eva L Feldman; Eleonora Aronica; Giovanni Nardo; Donatienne Van Weehaeghe; Elena Niccolai; Nikolina Prtenjaca; Stacey A Sakowski; Caterina Bendotti; Letizia Mazzini
Journal:  Neurosci Biobehav Rev       Date:  2021-06-19       Impact factor: 9.052

Review 10.  The Chitinases as Biomarkers for Amyotrophic Lateral Sclerosis: Signals From the CNS and Beyond.

Authors:  Nayana Gaur; Caroline Perner; Otto W Witte; Julian Grosskreutz
Journal:  Front Neurol       Date:  2020-05-27       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.